Companies collaborate to provide advanced genomic testing services to cancer drug developers
MolecularMD has joined with Personal Genome Diagnostics Inc. to market a comprehensive range of medical services to the oncology sector.
Personal Genome Diagnostics Inc. (PGDx; MD, USA) is to partner with MolecularMD (OR, USA), a specialist in molecular diagnostics for oncology applications, over the launch of a suite of comprehensive personalized medicine services targeted at cancer researchers and drug developers. The collaboration will draw on PGDx’s expertise in next-generation sequencing-based cancer biomarker discovery, in addition to MolecularMD’s capabilities in the development, validation and global delivery of cancer companion diagnostics.
According to a press release from PGDx, the alliance plans to design and provide a unique and specialized service to the pharmaceutical and biotechnology industry, which is intended to extend over the entire spectrum of genomic and clinical trial services employed in new drug R&D and clinical development. Under the terms of the agreement, the two organizations will co-market the other’s services to their pharmaceutical and biotechnology customers.
“PGDx has unique capabilities that supplement the growing menu of advanced genomic services MolecularMD provides to oncology drug developers,” commented Glenn Miller, Executive Vice President and Chief Technology Officer of MolecularMD. “The combination of our distinctive sets of expertise and common commitment to translating progress in cancer genomics into high quality tools for drug developers and clinicians should make this a valuable collaboration.”
